•  
  •  
 

Abstract

Hospital-acquired Clostridium difficile infection (CDI) has become one of the global threats because the incidence has increased in recent decades. This nosocomial infection is closely related to antibiotic use in health services and is commonly found in the elderly. Antibiotics can promote colonization and CDI by intestinal microbiota dysbiosis and complex innate immune system activation. The manifestation also has a wide spectrum, ranging from mild diarrhea to fulminant colonic mucosal necrosis. Given that not all colonized subjects will be infected, further investigations such as toxigenic culture, nucleic-acid detection, and stool immunologic tests are only useful in symptomatic cases. In all CDI cases, an effort to control and prevent infections, including rational use of antibiotics, is warranted. Besides the use of antibiotics to eradicate the bacteria, surgery is often indicated in fulminant cases—another novel therapy for recurrent CDI as follows fecal microbiota transplantation, antitoxin antibody, and novel antibiotics.

References

1. Heimann SM, Cruz Aguilar MR, Mellinghof S, Vehreschild M. Economic burden and cost-effective management of Clostridium difficile infections. Med Mal Infect. 2018;48(1):23-9. 2. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. 3. Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, et al. Underdiagnosis of Clostridium difficile across Europe: The european, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014;14(12):1208-19. 4. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the united states. N Engl J Med. 2015;372(9):825-34. 5. Hensgens MP, Goorhuis A, van Kinschot CM, Crobach MJ, Harmanus C, Kuijper EJ. Clostridium difficile infection in an endemic setting in the netherlands. Eur J Clin Microbiol Infect Dis. 2011;30(4):587-93. 6. Deshpande A, Borren NZ, Ghadermarzi S, Hutfless S, Ananthakrishnan AN. The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PLoS One. 2017;12(5):e0176797. 7. Hunter JC, Mu Y, Dumyati GK, Farley MM, Winston LG, Johnston HL, et al. Burden of nursing home-onset Clostridium difficile infection in the united states: estimates of incidence and patient outcomes. Open Forum Infect Dis. 2016;3(1):ofv196. 8. Weiner LM, Fridkin SK, Aponte-Torres Z, Avery L, Coffin N, Dudeck MA, et al. Vital signs: Preventing antibiotic-resistant infections in hospitals - united states, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(9):235-41. 9. Seugendo M, Janssen I, Lang V, Hasibuan I, Bohne W, Cooper P, et al. Prevalence and strain characterization of Clostridioides (Clostridium) difficile in representative regions of Germany, Ghana, Tanzania and Indonesia - a comparative multi-center crosssectional study. Front Microbiol. 2018;9:1843. 10. Collins DA, Gasem MH, Habibie TH, Arinton IG, Hendriyanto P, Hartana AP, et al. Prevalence and molecular epidemiology of Clostridium difficile infection in indonesia. New Microbes New Infect. 2017;18:34-7. 11. Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset Clostridium difficile infections in a large healthcare system. Clin Infect Dis. 2018;66(12):1957-9. 12. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: Update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881-91. 13. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742-8. 14. Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500-15. 15. Wijarnpreecha K, Sornprom S, Thongprayoon C, Phatharacharukul P, Cheungpasitporn W. Nasogastric tube and outcomes of Clostridium difficile infection: A systematic review and metaanalysis. J Evid Based Med. 2018;11(1):40-5. 16. Schaffler H, Breitruck A. Clostridium difficile - from colonization to infection. Front Microbiol. 2018;9:646. 17. Durovic A, Widmer AF, Tschudin-Sutter S. New insights into transmission of Clostridium difficile infection-narrative review. Clin Microbiol Infect. 2018;24(5):483-92. 18. Zhang L, Dong D, Jiang C, Li Z, Wang X, Peng Y. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic c. Difficile colonization. Anaerobe. 2015;34:1-7. 19. Vincent C, Manges AR. Antimicrobial use, human gut microbiota and Clostridium difficile colonization and infection. Antibiotics (Basel). 2015;4(3):230-53. 20. Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol. 2015;63(2):193-202. 21. Gateau C, Couturier J, Coia J, Barbut F. How to: Diagnose infection caused by Clostridium difficile. Clin Microbiol Infect. 2018;24(5):463-8. 22. Burke KE, Lamont JT. Clostridium difficile infection: A worldwide disease. Gut Liver. 2014;8(1):1-6. 23. Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87(11):1106-17. 24. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987-94. 25. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: A systematic review. JAMA. 2015;313(4):398-408. 26. Peng Z, Ling L, Stratton CW, Li C, Polage CR, Wu B, et al. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018;7(1):15. 27. Daneman N, Guttmann A, Wang X, Ma X, Gibson D, Stukel TA. The association of hospital prevention processes and patient risk factors with the risk of Clostridium difficile infection: a populationbased cohort study. BMJ Qual Saf. 2015;24(7):435-43. 28. Freedberg DE, Salmasian H, Cohen B, Abrams JA, Larson EL. Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed. JAMA Internal Medicine. 2016;176(12):1801. 29. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Revd. 2017;3:CD004610. 30. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305-17.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.